Spencer Kubo, MD, has been named senior vice president and global medical director of Acorn Cardiovascular (St. Paul, Minnesota). Previously, Kubo was a member of the cardiovascular division of the University of Minnesota, where he held the positions of co-director of clinical cardiology and medical director of the heart failure/heart transplantation program. Acorn develops less-invasive devices for the treatment of heart failure.
Andrew Lux, PhD, has been named president and chief operating officer of BioMec (Cleveland, Ohio). Lux previously was vice president, operations and R&D, of the cardiac surgery division of Medtronic. Biomec is a biomedical engineered products and systems company.
Richard Miller plans to retire as corporate vice president, North America, for Edwards Lifesciences (Irvine, California). Miller has been part of Edwards and its predecessor organizations for about 30 years. He assumed his current post in January, prior to which he headed Edwards' critical care business.
Robert Scott, MD, has joined Miravant Medical Technologies (Santa Barbara, California) as president of its Miravant Cardiovascular (MCI) subsidiary. Scott previously held senior positions in cardiovascular medical research at Eli Lilly and Co. He will be responsible for directing the strategic development of MCI, including science, technology and business. MCI is developing its intravascular and intracoronary PhotoPoint photodynamic therapy to treat cardiovascular diseases with light-activated pharmaceuticals. Its drug candidates and endovascular light catheters are in advanced preclinical testing for angioplasty-related restenosis, atherosclerosis and vascular graft intimal hyperplasia.
Rod Wilson has been named chief operating officer of Syn X Pharma (Toronto, Ontario). Most recently, he was vice president, sales, for GlaxoSmithKline Canada. Syn X is developing diagnostics for cardiovascular diseases, including heart failure and hypertension, as well as for diabetes and central nervous system diseases such as Alzheimer's.
Steve Jwanouskos has been named vice president of clinical and regulatory affairs for TransVascular (Menlo Park, California), a developer of catheter-based products that use the "vascular highway" as an avenue for accessing treatment sites. In addition, Ludwik Firek, PhD, has been named director of European clinical development. Jwanouskos previously was senior director of regulatory affairs for Boston Scientific's EP Technologies division, and Firek was European marketing director for the Biosense Webster division of Johnson & Johnson.